journal article·2021-06-22

Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles

Uri Elia, Srinivas Ramishetti, Ronit Rosenfeld, Niels Dammes, Erez Bar-Haim, Gonna Somu Naidu, Efi Makdasi, Yfat Yahalom-Ronen, Hadas Tamir, Nir Paran, Ofer Cohen, Dan Peer

ACS Nano· Volume 15· Issue 6
Publisher page

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causal agent of COVID-19 and stands at the center of the current global human pandemic, with death toll exceeding one million. The urgent need for a vaccine has led to the development of various immunization approaches. mRNA vaccines represent a cell-free, simple, and rapid platform for immunization, and therefore have been employed in recent studies toward the development of a SARS-CoV-2 vaccine. Herein, we present the design of an mRNA vaccine, based on lipid nanoparticles (LNPs)-encapsulated SARS-CoV-2 human Fc-conjugated receptor-binding domain (RBD-hFc). Several ionizable lipids have been evaluated in vivo in a luciferase (luc) mRNA reporter assay, and two leading LNPs formulations have been chosen for the subsequent RBD-hFc mRNA vaccine strategy. Intramuscular administration of LNP RBD-hFc mRNA elicited robust humoral response, a high level of neutralizing antibodies and a Th1-biased cellular response in BALB/c mice. The data in the current study demonstrate the potential of these lipids as promising candidates for LNP-based mRNA vaccines in general and for a COVID19 vaccine in particular.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · RNA Interference and Gene Delivery · Animal Virus Infections Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel

Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel

Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel

Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel

Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona 76100, Israel

Funding

Lewis Trust

References (39)

Show source-provided references
1. Coronavirus Disease (COVID-19) , World Health Organization, Oct. 11, 2020; https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf (accessed 2020-10-12).
2. Draft Landscape of COVID-19 Candidate Vaccines , World Health Organization; https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed 2020-10-02).
3. 10.1056/NEJMoa202248310.1056/NEJMoa2022483 ↗
4. 10.1056/NEJMoa171615310.1056/NEJMoa1716153 ↗
5. 10.3109/1061186X.2016.117258710.3109/1061186X.2016.1172587 ↗
6. 10.1038/nbt.160210.1038/nbt.1602 ↗
7. 10.1016/j.addr.2020.07.02210.1016/j.addr.2020.07.022 ↗
8. 10.1016/S0140-6736(17)31665-310.1016/S0140-6736(17)31665-3 ↗
9. 10.1016/j.ymthe.2017.03.03510.1016/j.ymthe.2017.03.035 ↗
10. 10.1016/j.vaccine.2018.01.02910.1016/j.vaccine.2018.01.029 ↗
11. 10.1038/nature2142810.1038/nature21428 ↗
12. 10.1038/ncomms1463010.1038/ncomms14630 ↗
13. 10.1038/s41586-020-2814-710.1038/s41586-020-2814-7 ↗
14. 10.1002/adma.20190612810.1002/adma.201906128 ↗
15. 10.1038/s41586-020-2179-y10.1038/s41586-020-2179-y ↗
16. 10.1002/emmm.20120137910.1002/emmm.201201379 ↗
17. 10.1021/acs.bioconjchem.5b0030510.1021/acs.bioconjchem.5b00305 ↗
18. Schmidt S. R. · Curr. Opin. Drug Discovery Dev. · 2009 · 12 · 284
19. 10.3109/07388551.2016.116332310.3109/07388551.2016.1163323 ↗
20. 10.1007/82_2019_15410.1007/82_2019_154 ↗
21. 10.1002/jssc.20200076510.1002/jssc.202000765 ↗
22. 10.1016/j.cell.2020.05.01510.1016/j.cell.2020.05.015 ↗
23. 10.1038/s41423-020-0401-310.1038/s41423-020-0401-3 ↗
24. 10.1080/17425247.2019.166955810.1080/17425247.2019.1669558 ↗
25. 10.1016/j.omtn.2019.01.01310.1016/j.omtn.2019.01.013 ↗
26. 10.4161/hv.2556110.4161/hv.25561 ↗
27. Lainšček, D.; Fink, T.; Forstnerič, V.; Hafner-Bratkovič, I.; Orehek, S.; Strmšek, Ž.; Manček-Keber, M.; Pečan, P.; Esih, H.; Malenšek, Š.; Aupič, J.; Dekleva, P.; Plaper, T.; Vidmar, S.; Kadunc, L.; Benčina, M.; Omersa, N.; Anderluh, G.; Pojer, F.; Lau, K.; Immune Response to Vaccine Candidates Based on Different Types of Nanoscaffolded RBD Domain of the SARS-CoV-2 Spike Protein. bioRxiv (Immunology) , Aug. 28, 2020, 2020.08.28.244269. https://www.biorxiv.org/content/10.1101/2020.08.28.244269v1 (accessed 2020-10-12).10.1101/2020.08.28.244269 ↗
28. 10.1038/s41586-020-2599-810.1038/s41586-020-2599-8 ↗
29. 10.1038/s41392-020-00402-510.1038/s41392-020-00402-5 ↗
30. 10.1016/j.vaccine.2020.09.05810.1016/j.vaccine.2020.09.058 ↗
31. 10.1016/j.vaccine.2006.10.03110.1016/j.vaccine.2006.10.031 ↗
32. Sun, S.; He, L.; Zhao, Z.; Gu, H.; Fang, X.; Wang, T.; Yang, X.; Chen, S.; Deng, Y.; Li, J.; Zhao, J.; Li, L.; Li, X.; He, P.; Li, G.; Li, H.; Zhao, Y.; Gao, C.; Lang, X.; Wang, X., Recombinant Fc-Fusion Vaccine of RBD Induced Protection against SARS-CoV-2 in Non-Human Primate and Mice. bioRxiv (Immunology) , Nov. 30, 2020, 2020.11.29.402339. https://www.biorxiv.org/content/10.1101/2020.11.29.402339v1 (accessed 2020-10-12).10.1101/2020.11.29.402339 ↗
33. 10.1126/science.abb892310.1126/science.abb8923 ↗
34. 10.1016/j.immuni.2020.07.01910.1016/j.immuni.2020.07.019 ↗
35. 10.1038/s41422-020-00392-710.1038/s41422-020-00392-7 ↗
36. 10.1038/s41422-020-0387-510.1038/s41422-020-0387-5 ↗
37. 10.1016/j.cell.2020.07.02410.1016/j.cell.2020.07.024 ↗
38. 10.1038/s41467-020-18159-410.1038/s41467-020-18159-4 ↗
39. 10.1038/s41467-020-20228-710.1038/s41467-020-20228-7 ↗